Profile for European Patent Office Patent: 2734522
✉ Email this page to a colleague
| Country | SPC | SPC Expiration |
|---|---|---|
| Netherlands | 301097 | ⤷ Start Trial |
| Lithuania | PA2021004 | ⤷ Start Trial |
| Denmark | CA 2021 00007 | ⤷ Start Trial |
| Luxembourg | LUC00202 | ⤷ Start Trial |
| Germany | 122021000020 | ⤷ Start Trial |
| Belgium | 2021C/512 | ⤷ Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 2734522
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| 10,239,883 | Jul 11, 2032 | Astrazeneca | CALQUENCE | acalabrutinib |
| 10,239,883 | Jul 11, 2032 | Astrazeneca | CALQUENCE | acalabrutinib maleate |
| 9,290,504 | Jul 11, 2032 | Astrazeneca | CALQUENCE | acalabrutinib |
| 9,290,504 | Jul 11, 2032 | Astrazeneca | CALQUENCE | acalabrutinib maleate |
| 9,758,524 | Jul 11, 2032 | Astrazeneca | CALQUENCE | acalabrutinib |
| 9,758,524 | Jul 11, 2032 | Astrazeneca | CALQUENCE | acalabrutinib maleate |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
